ערך בספרים למניה: Predictive Oncology Corp (POAI)

The demand for AI modeling in oncology, coupled with strict control over R&D expenditures, supports the business stability of Predictive Oncology (POAI). The book value per share indicator confirms asset transparency, while the -100.11 metric indicates the status of current capitalization. The development of the B2B segment via the biobank is complemented by cost optimization through the outsourcing of test system production and the use of cloud IT infrastructure for data analysis.

This indicator reflects the equity per share, serving as a measure of the intrinsic value of assets net of liabilities. By analyzing the book value per share trend, an investor assesses the capitalization of the Predictive Oncology (POAI) IT ecosystem, where the value of proprietary databases and bioinformatics network effects forms the foundation of financial stability and investment security.